**[211] RESOLVING THE PIVOTAL ISSUE OF MICROBIOME THERAPEUTICS**

**Didi Daboush1, 1 Company**

**Questions for Biotech/Pharma; Medical Devices and Health IT/Digital Health categories are:**

* **Investment Rational**
MyBiotics is a life science startup active in the microbiome therapeutics market. The company’s innovative technologies; MyCrobeTM and SuperDonor enable efficient delivery of live and colonizing bacteria to restore microbiome balance and bring real clinical effect. These technologies put the company in the front line of the new emerging field of Pharmabiotics using bacteria as a drug.
* **Business Strategy**
MyBiotics is focusing on drug development while its technological achievements and tools may be translated to address the same needs in the food and food supplement market.
* **Core Technology**

**MYCROBETM** Is a live and colonizing bacteria delivery technology developed by MyBiotics.

Our bacteria survive the harsh body and production conditions and make microencapsulation and coating unnecessary. The colonized bacteria is a promising step toward a real long-lasting clinical effect.

***SuperDonor*** technology was designed to bring whole microbiome recovery and restoration and replace fecal transplant as a treatment and screening process. The first products based on the SuperDonor is for *C. difficle* infections.

* **Product Profile/Pipeline**

***C. difficle infection.*** *Using the SuperDonor technology, laboratory grown whole microbiome transplantation will be used to cure C. difficle patients thus replacing the currently used fecal transplantations.*

**Anti-inflammatory**

* **What’s Next?**

Three successful pre-clinical experiments have been accomplished and prove the efficiency of delivery and colonization of bacteria. First in-men experiment to validate MyCrobe technology is due to begin at Q3 2016. MyBiotics is launched the development process of the first SuperDonor product to be used for C. difficle infections with clinical trial due to begin at Q2 2017.